American College of Medical Genetics and Genomics (ACMG), 2026

BIMZELX®, BRIVIACT®, CIMZIA®, FINTEPLA®, KYGEVVI™, NAYZILAM®, RYSTIGGO®, ZILBRYSQ®, UCBCares®, and UCBCOMPASS® are (registered) trademarks of the UCB Group of Companies. All other trademarks and registered marks are the property of their respective holders.

©2026 UCB, Inc., Smyrna, GA 30080. All rights reserved. All data collected on this site is governed by UCB’s Privacy Policy, Cookies Policy, as well as the site Terms and Conditions. This site is intended for US Healthcare Professionals only.

US-OT-2600001 February 2026

Sticky notice

RHEUMATOLOGY

The Women's Health Fellowship Program application is now closed. Learn More

RARE DISEASE

KYGEVVI^™ (doxecitine and doxribtimine) powder for oral solution 2 g/2 g is now FDA approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adult and pediatric patients with an age of symptom onset on or before 12 years.

UCB Medical is now on LinkedIn. Follow us